Cytosolic 5'-Nucleotidase 1A (cN-1A) Antibody (IgG)

There are no preparation instructions.

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

CYTOSOLIC 5' NUCLEOTIDASE

*Important Information on Lab Test Processing Times: Ulta Lab Tests is committed to informing you about the processing times for your lab tests processed through Quest Diagnostics. Please note that the estimated processing time for each test, indicated in business days, is based on data from the past 30 days across the 13 Quest Diagnostics laboratories for each test. These estimates are intended to serve as a guide and are not guarantees. Factors such as laboratory workload, weather conditions, holidays, and the need for additional testing or maintenance can influence actual processing times. We aim to offer estimates to help you plan accordingly. Please understand that these times may vary, and processing times are not guaranteed. Thank you for choosing Ulta Lab Tests for your laboratory needs.

The Cytosolic 5'-Nucleotidase 1A (cN-1A) Antibody (IgG) test contains 1 test with 1 biomarker.

Clinical Significance

Cytosolic 5'-Nucleotidase 1A (cN-1A) Antibody (IgG) - The cN-1A Ab assay is a useful aid for the diagnosis of inclusion body myositis (IBM). The analytical sensitivity of this assay is 35-70%, based on published reports [1, 2]. In our validation study with 120 healthy adult subjects, 1.7% had a positive cN-1A Ab result and 6.7% had an equivocal result. However, published reports and our own internal studies suggest that patients with Sjogren’s syndrome, systemic lupus erythematosus, dermatomyositis (DM), or polymyositis (PM), are significantly more likely to have a positive cN-1A Ab result [1, 2, 3]. In contrast, patients presenting clinically with IBM rarely produce autoantibodies associated with a diagnosis of DM or PM [3]. Therefore, cN-1A Ab results must be interpreted in context with other details of the patient’s clinical evaluation.

Reference Range(s)

<15 Units Negative
15-19 Units Borderline
≥20 Units Positive

Alternative Name(s)

MUP44 AB,cN1A,sIBM,Inclusion Body Myositis,Anti-IBM,NT5C1A,sporadic IBM

Customer Reviews